Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.

被引：0
|
作者：
Li, Jian
Huang, Jing
Ba, Yi
Cao, Baoshan
Luo, Suxia
Li, Wenhua
Song, Zhengbo
Zhu, Liangjun
Xiong, Jianping
An, Guangyu
Zhang, Yanqiao
Li, Zhihua
Li, Yongsheng
Gu, Yanhong
Li, Xingya
Huang, Chenghui
Fu, Qihan
Hu, Changlu
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Med Oncol,Canc Hosp, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[4] Peking Univ Third Hosp, Canc Chemotherapy & Radiat Dept, Beijing, Peoples R China
[5] Zhengzhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Gastrointestinal Med Oncol, Shanghai, Peoples R China
[7] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[8] Jiangsu Canc Hosp, Nanjing, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China
[10] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China
[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[12] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[13] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[14] Jiangsu Prov Hosp, Nanjing, Peoples R China
[15] Zhengzhou Univ, Affiliated Hosp 1, Oncol Dept, Zhengzhou, Peoples R China
[16] Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China
[17] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[18] Anhui Prov Canc Hosp, Ward Med Oncol 4, Hefei, Peoples R China
[19] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe
    Italiano, Antoine
    Heist, Rebecca S.
    Han, Ji-Youn
    Deming, Dustin
    Spira, Alexander
    Sabari, Joshua
    Chisamore, Michael J.
    Fink, Aaron
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    Pruthi, Aarohan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 137 - 138
  • [42] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin H.
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe Alexandre
    Italiano, Antoine
    Heist, Rebecca Suk
    Han, Ji-Youn
    Deming, Dustin A.
    Spira, Alexander I.
    Sabari, Joshua K.
    Chisamore, Michael Jon
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] KontRASt-01 update: safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Schuler, M.
    Cassier, P. A.
    Dooms, C.
    Gazzah, A.
    Felip, E.
    Steeghs, N.
    Rohrberg, K. S.
    De Braud, F.
    Solomon, B.
    Tan, D. S.
    Yamamoto, N.
    Loong, H. H.
    Cho, B. C.
    Wolf, J.
    Lin, C. -C
    Negrao, M.
    Werner, L.
    Cui, X.
    Farago, A. F.
    de Miguel, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 147 - 148
  • [44] KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Cassier, Philippe Alexandre
    Dooms, Christophe Alfons
    Gazzah, Anas
    Felip, Enriqueta
    Steeghs, Neeltje
    Rohrberg, Kristoffer Staal
    De Braud, Filippo G.
    Solomon, Benjamin J.
    Schuler, Martin H.
    Tan, Daniel Shao-Weng
    Yamamoto, Noboru
    Loong, Herbert H. F.
    Cho, Byoung Chul
    Wolf, Juergen
    Lin, Chia-Chi
    Negrao, Marcelo Vailati
    Werner, Lillian
    Cui, Xiaoming
    Farago, Anna F.
    de Miguel, Maria J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.
    Hong, David S.
    Morris, Van Karlyle
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina Anne
    Kee, Bryan K.
    Zinner, Ralph
    Fogelman, David R.
    Mistry, Reena
    Shureiqi, Imad
    Meric-Bernstam, Funda
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] A retrospective analysis of the prognostic impact of KRAS G12D mutation in patients with RAS-mutated metastatic colorectal cancer.
    Hirose, Toshiharu
    Matsuguma, Kunihito
    Hirano, Hidekazu
    Okita, Natsuko Tsuda
    Shoji, Hirokazu
    Takashima, Atsuo
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 105 - 105
  • [47] Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
    Gray, Jhanelle E.
    Hsu, Hil
    Younan, Diana
    Suri, Gaurav
    Chia, Victoria
    Spira, Alexander
    Johnson, Melissa
    LUNG CANCER, 2023, 181
  • [48] Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRAS G12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report
    Stratton, Natalie
    Thompson, Jonathan
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
  • [49] KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
    Cappuzzo, Federico
    Castro, Gilberto
    Kang, Jin-Hyoung
    Wu, Yi-Long
    Brustugun, Odd Terje
    Cheema, Parneet Kaur
    Owonikoko, Taofeek K.
    Longin, Anne-Sophie
    Boran, Aislyn
    Duan, Jiawei
    Caparica, Rafael
    Loong, Herbert H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC
    Cappuzzo, F.
    Castro Junior, G.
    Kang, J. H.
    Wu, Y. L.
    Brustugun, O. T.
    Cheema, P. K.
    Owonikoko, T. K.
    Longin, A. S.
    Duan, J.
    Caparica, R.
    Loong, H. H. F.
    Chan, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E14 - E14
12345